Icovamenib shows promise in diabetes treatment with beta-cell restoration

REDWOOD CITY, Calif. - Biomea Fusion, Inc. (NASDAQ:BMEA), a clinical-stage company focused on diabetes and obesity medicines, has presented new data at the Advanced Technologies & Treatments for Diabetes (ATTD) 2025 Conference in Amsterdam, indicating that its investigational drug icovamenib may have disease-modifying potential for type 2 diabetes.

The presented data suggest that icovamenib, a covalent menin inhibitor, has the ability to sustain reductions in HbA1c levels and improve beta-cell function even three months after treatment cessation. This finding is based on a correlation between increased C-peptide levels and reduced HbA1c in patients, particularly those with severe insulin deficiency who are already on antihyperglycemic agents. InvestingPro analysis shows the company maintains a strong financial position with more cash than debt and a healthy current ratio of 3.39, though it’s currently burning through cash rapidly as it advances its clinical programs.

Icovamenib-treated patients demonstrated a persistent increase in C-peptide levels, a biomarker for endogenous insulin production, suggesting long-term improvements in beta-cell function. The most notable response was observed in a prespecified group of beta-cell deficient patients, who achieved a statistically significant placebo-adjusted mean reduction in HbA1c of 1.47% at Week 26 after only 12 weeks of treatment.

In addition, preclinical in vivo experiments showed that icovamenib enhanced the responsiveness of human islets to GLP-1-based medicines, increasing the expression levels of both the GLP-1 receptor and intracellular insulin.

Severe Insulin Deficient Diabetes, which is estimated to affect over 100 million people worldwide, represents an underserved patient population within type 2 diabetes. The potential of icovamenib to restore beta-cell function and improve insulin production and secretion could be a significant advancement for patients with this condition.

Juan Pablo Frías, MD, Chief Medical Officer of Biomea Fusion, commented on the potential role of icovamenib in improving beta-cell function and its synergistic benefits when combined with GLP-1-based medicines.

The data from the ATTD 2025 Conference will be published in the Journal of Diabetes Technology & Therapeutics, and the symposium slides are available on Biomea Fusion’s Investor Relations page.

Biomea Fusion is advancing icovamenib through clinical trials, aiming to bring a potentially first-in-class, disease-modifying therapy to patients with type 2 diabetes. The company’s focus is on developing oral covalent small molecules that offer advantages such as greater target selectivity and more durable responses.

This article is based on a press release statement from Biomea Fusion, Inc. While the company’s stock currently trades below InvestingPro’s Fair Value estimate, investors should note that analysts have set price targets ranging from $11 to $54, reflecting the potential upside if clinical trials succeed. For deeper insights into Biomea’s financial health and growth prospects, including 12 additional ProTips and comprehensive valuation metrics, explore the full Pro Research Report available on InvestingPro.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.